Immunotherapy significantly improves overall survival for advanced NSCLC patients

FHS
July 7, 2023
3:13 am

A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.

Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US (21%) and EMEA (18%) –improvement of EBITDA* margin to 17% – Biotech Investments

Medartis Holding AG / Key word(s): Half Year Results 20-Aug-2024 / 07:05 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The

August 21, 2024

International Experts Highlight Demand for Diagnostic Innovations as PenKid’s Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools – Biotech Investments

Issuer: SphingoTec GmbH / Key word(s): Research Update/Conference 06.09.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. International experts

September 7, 2023

Do we simply not care about old people?

The covid-19 pandemic would be a wake-up call for America, advocates for the elderly predicted: incontrovertible proof that the nation wasn’t doing enough to care

February 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.